Stereotaxis rises after FDA clears new heart-procedure platform

Stereotaxis

06/04/2026 13:35

** Shares of medical robotics firm Stereotaxis STXS.A rise 9% to $2 premarket

** Co says it has won FDA clearance for its Synchrony system to modernize cardiac catheterization labs, which are rooms where doctors perform heart procedures using thin tubes inserted into blood vessels

** Co says Synchrony combines video and controls from multiple devices on one high-definition screen, aiming to simplify workflow, improve efficiency and enable secure remote collaboration

** Brokerage TD Cowen says STXS has generated strong initial demand for the technology, which it projects will deliver over $3 million in revenue in 2026 as multiple US hospitals standardize their EP labs with it

** Brokerage adds STXS plans to complete the development of the first AI features that will be incorporated into Synchrony this year

** Brokerage reiterates Stereotaxis at ‘Buy’, keeps PT at $5

** As of last close, shares down ~19% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))